- Home
- GDTC vs NYC Comparison
GDTC vs NYC Comparison
Compare GDTC & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- NYC
- Stock Information
- Founded
- GDTC 2018
- NYC 2013
- Country
- GDTC Singapore
- NYC United States
- Employees
- GDTC N/A
- NYC N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- NYC Real Estate
- Sector
- GDTC Health Care
- NYC Finance
- Exchange
- GDTC Nasdaq
- NYC Nasdaq
- Market Cap
- GDTC 21.5M
- NYC 24.9M
- IPO Year
- GDTC 2023
- NYC N/A
- Fundamental
- Price
- GDTC $2.17
- NYC $9.89
- Analyst Decision
- GDTC Buy
- NYC
- Analyst Count
- GDTC 1
- NYC 0
- Target Price
- GDTC $5.00
- NYC N/A
- AVG Volume (30 Days)
- GDTC 21.1K
- NYC 7.6K
- Earning Date
- GDTC 01-01-0001
- NYC 11-11-2025
- Dividend Yield
- GDTC N/A
- NYC N/A
- EPS Growth
- GDTC N/A
- NYC N/A
- EPS
- GDTC N/A
- NYC N/A
- Revenue
- GDTC $573,193.00
- NYC $54,865,000.00
- Revenue This Year
- GDTC $5.37
- NYC $8.40
- Revenue Next Year
- GDTC N/A
- NYC $1.62
- P/E Ratio
- GDTC N/A
- NYC N/A
- Revenue Growth
- GDTC 63.03
- NYC N/A
- 52 Week Low
- GDTC $1.65
- NYC $7.89
- 52 Week High
- GDTC $4.05
- NYC $16.30
- Technical
- Relative Strength Index (RSI)
- GDTC 62.97
- NYC 43.51
- Support Level
- GDTC $1.95
- NYC $9.46
- Resistance Level
- GDTC $2.30
- NYC $10.25
- Average True Range (ATR)
- GDTC 0.09
- NYC 0.64
- MACD
- GDTC 0.01
- NYC 0.09
- Stochastic Oscillator
- GDTC 70.29
- NYC 56.95
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.